{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.58","value":"119.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"title":"Mirvetuximab soravtansine at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.11","value":"127.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"}],"units":"Participants"}],"title":"Mirvetuximab soravtansine at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"54.04","value":"186.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"title":"Total M9346A antibody at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"71.46","value":"218.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"}],"units":"Participants"}],"title":"Total M9346A antibody at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.99","value":"73.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"DM4 at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.12","value":"80.62"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"DM4 at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.23","value":"122.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"S-methyl DM4 at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.47","value":"130.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"S-methyl DM4 at Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"description":"PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, total M9346A antibody, DM4, and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received mirvetuximab soravtansine 6.0 mg/kg (calculated based on AIBW) on Day 1 of Cycle 1 and Cycle 3.","id":"OG000","title":"Mirvetuximab Soravtansine 6.0 mg/kg AIBW"}],"paramType":"MEAN","populationDescription":"PK Population included all participants who received at least 1 infusion of mirvetuximab soravtansine and had evaluable PK data. 'Overall number of participants analyzed' = participants who received mirvetuximab soravtansine at 6 mg/kg AIBW. 'Number analyzed' = participants evaluable for this outcome for specified categories.","reportingStatus":"POSTED","timeFrame":"Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)","title":"Terminal Half-Life (t1/2) of Mirvetuximab Soravtansine,Total M9346A Antibody, DM4, and S-Methyl DM4 at RP2D","type":"SECONDARY","unitOfMeasure":"hours"}